Clik here to view.
Lilly exec points to Medicare as more pay full list price for Zepbound than...
A larger share of Medicare patients are having to pay the full list price for Lilly’s obesity drug Zepbound than for Mounjaro, a top executive said at a recent banking conference. Patrik Jonsson,...
View ArticleFDA funding would stay flat under House bill scheduled for markup
A House panel later today is scheduled to mark up the FDA’s appropriations bill for fiscal year 2025, the beginning of Congress’ process for funding the agency in the upcoming year. Under the proposal,...
View ArticleAvidity eyes registrational path for rare muscle disease drug after early...
Avidity Biosciences’ antibody oligonucleotide conjugate has shown signs of efficacy in an early-stage test in patients with a rare muscle-wasting disease. Just last month, Leerink analysts were...
View ArticleLife science CDMO Agilent cuts over 180+ employees in California
Agilent Technologies, a life science CDMO and laboratory product developer, is laying off 184 staffers across six locations in California. The company previously said it had restructuring plans this...
View ArticleChina biotech ban does not make the cut as add-on to defense spending bill
A bipartisan bill that would essentially ban US biotech companies from using certain Chinese suppliers failed to muster the support needed to hitch a ride to passage as part of a wider spending bill...
View ArticleUltragenyx reports longer-term Phase 2 data for rare bone disorder drug in...
Four years after betting up to $304 million on a drug for a rare genetic bone disorder, Ultragenyx and its partner Mereo BioPharma reported positive data in a Phase 2/3 trial. The two companies are...
View ArticleClik here to view.
Foresite Capital closes $900M sixth fund, backing the likes of Xaira and IPO...
Foresite Capital, fresh off one of the largest-ever biotech launches, has closed on its sixth fund just 13 years into its life as an incubator and investor in life sciences startups. At $900 million,...
View ArticleAlzheon raises $100M; Regeneron ends mid-stage trial
Plus, news about Genmab, BioNTech, Bristol Myers Squibb, BridgeBio, Junshi, Tevogen, Actuate, GSK, Ochre Bio, Evotec and ProKidney: Alzheon raises $100M Series E: The company’s lead program is...
View ArticleJ&J agrees to $700M talc settlement with 42 states and DC
Johnson & Johnson inked a $700 million settlement deal with 42 states and Washington, DC, on Tuesday to resolve claims that it deceptively marketed its talc products. As part of the deal, J&J...
View ArticleClik here to view.
Pfizer strikes an R&D partnership with Flagship's ProFound as it looks for...
Pfizer is opening up another road to the obesity market, announcing a partnership with one of Flagship Pioneering’s startups to identify new molecules and targets for the condition. The partnership...
View ArticleStates join Oklahoma effort to convince Supreme Court to let them regulate PBMs
The majority of states have signed onto an amicus brief asking the US Supreme Court to decide whether they have the right to regulate pharmacy benefit managers, part of an ongoing debate about who has...
View ArticleLilly, Eisai and Biogen seek more specifics in FDA guidance on early...
Alzheimer’s drug manufacturers are asking the FDA to give them more clarity on the different stages of the disease in comments they’ve submitted on the agency’s draft guidance for developing drugs for...
View ArticleGilead's M&A appetite is for deals in the 'mid-single-digit billions,' CEO says
Gilead CEO Daniel O’Day says the company will likely look for more deals like its $4.3 billion purchase of CymaBay Therapeutics over the next few years, rather than big buys costing tens of billions of...
View ArticlePfizer’s Duchenne muscular dystrophy gene therapy fails Phase 3 trial
Pfizer’s Duchenne muscular dystrophy gene therapy failed to meet the primary and key secondary endpoints in a Phase 3 study, pointing to a bleak future for the program. The gene therapy failed to...
View ArticleOnly a third of employers and health plans cover GLP-1 drugs for weight loss,...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Companies still aren’t rushing to pay for their workers’ GLP-1 weight loss drugs, despite skyrocketing...
View ArticleClik here to view.
Former Merck scientists raise $85M to map and drug protein interactions in...
The surfaces of cells are studded with proteins used to communicate with neighbors and visitors. A new method for mapping them and their interactions is revealing clues for making cancer and immune...
View ArticleClik here to view.
Barinthus Bio to lay off 25% of its workforce and focus on just two programs
Barinthus Bio is shifting its focus to just two investigational candidates and cutting about 25% of its workforce in order to extend cash runway into the second quarter of 2026, the company announced...
View ArticleCara cuts oral pruritus drug after Phase 2/3 disappointment, seeks strategic...
Cara Therapeutics’ drug candidate has flopped in a mid-stage trial in people with moderate-to-severe itch due to a neurological disorder, prompting the company to terminate the program — the last one...
View Article'Speed is everything': Versant-backed immunology startup raises $125M with...
Another Versant Ventures startup announced a big funding round this week, and this one wants to move quickly. Santa Ana Bio said Thursday that it closed a $125 million Series B, bringing its total...
View ArticleAbbVie banks on second-gen TL1A program, licensing antibody from FutureGen
AbbVie is jumping into the TL1A space, inking a new deal with a Beijing-based biotech. The company said Thursday that it’s partnering with FutureGen Biopharmaceutical, licensing an anti-TL1A antibody...
View Article